皮质类固醇可降低艾滋病毒感染者的结核病死亡率:使用重建的个体患者数据进行系统审查和元分析
Alhassane Diallo1, Boubacar Djelo Diallo2,3, Oumou Hawa Diallo3
1Department of Public Health, Gamal Abdel Nasser University of Conakry, Conakry, Conakry, Guinea djuhany@gmail.com.
BMJ global health
|August 14, 2025
概括
辅助皮质类固醇显著降低了艾滋病毒感染者 (PLHIV) 接受结核病 (TB) 治疗的人的死亡率. 这项对四项RCT的元分析发现,12个月后死亡率降低了67%,带来了持续的好处.
科学领域:
- 传染性疾病 传染性疾病
- 临床医学 临床医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 结核病 (TB) 仍然是全球主要的死亡原因,特别是在艾滋病毒感染者 (PLHIV) 中.
- 在PLHIV中治疗结核病是复杂的,死亡率和机会性感染的风险增加.
- 正在探索辅助疗法,以改善这种脆弱人群的治疗结果.
研究的目的:
- 评估辅助皮质类固醇对接受结核病治疗的PLHIV患者死亡率的影响.
- 综合来自随机对照试验 (RCT) 关于在HIV-TB同时感染患者中使用皮质类固醇的证据.
主要方法:
- 一个系统的综述和对已发表的随机的安慰剂受控试验 (RCTs) 的元分析.
- 数据是从发表到2023年12月31日的研究中提取的,使用PubMed,CENTRAL和EMBASE.
- 从Kaplan-Meier曲线重建了个别患者的数据,并使用混合效应Cox回归模型进行分析.
主要成果:
- 包括4个RCT,包括873个PLHIV和各种形式的结核病 (脑膜炎,多叶膜炎,心周炎).
- 与安慰剂相比,辅助皮质类固醇在12个月内减少了67%的死亡率 (HR 0.33).
- 在整个随访期间 (HR 0.83),观察到持续的17%的死亡率降低,结核病脑膜炎的好处趋势.
结论:
- 辅助皮质类固醇与治疗结核病的PLHIV患者的死亡率降低有关.
- 这些发现表明,皮质类固醇在改善HIV-TB同时感染个体的存活率方面具有潜在的益处.
- 建议进行进一步的临床试验,以证实这些发现并指导临床实践.
更多相关视频
相关概念视频
Pulmonary Tuberculosis I
324
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
324
Pulmonary Tuberculosis V
239
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
239
Pulmonary Tuberculosis IV
204
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
204
COPD: Management Using Bronchodilators and Corticosteroids
310
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
310
Pulmonary Tuberculosis II
346
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
346
Pulmonary Tuberculosis III
443
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
443


